艾美疫苗提交13价肺炎疫苗上市申请
财中社11月1日电艾美疫苗（06660）发布公告，宣布其自主研发的13价结合肺炎疫苗已于2024年10月31日向国家药品监督管理局提交药品上市注册。这一疫苗在完成III期临床研究后，展现出良好的免疫原性和安全性，达到临床预设目标。同时，艾美疫苗的全资子公司已获得该产品的药品生产许可证。
根据辉瑞公司2023年报，全球13价结合肺炎疫苗的销售额约为64.4亿美元。艾美疫苗的产品在中国市场的预估渗透率为25.9%，而美国相应年龄组的渗透率超过80%。这表明，中国市场具有巨大的增长空间，预计到2030年，该产品的市场规模有望达到350亿元。新冠疫情之前，该产品曾是连续十年的全球疫苗销售冠军，全球对该疫苗的需求缺口高达1.8亿剂，艾美疫苗的上市将成为重要的供应商，显著提升公司的业绩。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10